SuperworthBoston Scientific BSX
- Market cap
- $66.2B
- PE
- 18.5×
- 10y median 67.0×
- Forward PE
- 14.1×
- 10y median 25.6×
- Price to sales
- 3.2×
- EV/EBIT
- 18.2×
- Revenue, 12 months
- $21B
- +14% on a year ago
- Net margin
- 17.5%
- Free cash flow yield
- 5.5%
Boston Scientific trades at 18.5× trailing earnings, cheaper than 89% of the last ten years. Revenue was $21B over the last twelve months, up 14% on a year earlier with a 18% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.5B+11% | $3.7B+15% | $3.9B+14% | $4.1B+15% | $4.2B+19% | $4.6B+22% | $4.7B+21% | $5.1B+23% | $5.1B+20% | $5.3B+16% | $5.2B+12% | $5.4B+8% | |
| Cost of revenue | $1.1B+13% | $1.1B+14% | $1.2B+16% | $1.3B+20% | $1.3B+19% | $1.5B+28% | $1.5B+20% | $1.6B+29% | $1.5B+16% | $1.6B+10% | $1.6B+9% | $1.6B−3% |
| Gross profit | $2.4B+11% | $2.6B+16% | $2.6B+13% | $2.9B+12% | $2.9B+19% | $3.1B+20% | $3.2B+21% | $3.4B+20% | $3.5B+22% | $3.7B+19% | $3.6B+13% | $3.8B+12% |
| R&D | $356M+5% | $363M+10% | $366M+9% | $383M+7% | $407M+14% | $459M+26% | $443M+21% | $526M+37% | $514M+26% | $569M+24% | $516M+17% | $554M+5% |
| SG&A | $1.2B+10% | $1.4B+19% | $1.4B+12% | $1.4B+7% | $1.6B+26% | $1.6B+17% | $1.6B+17% | $1.7B+19% | $1.7B+12% | $1.8B+14% | $1.8B+12% | $1.8B+5% |
| $693M+94% | $584M+45% | $675M+22% | $520M+1% | $733M+6% | $675M+16% | $921M+36% | $819M+58% | $1B+43% | $825M+22% | $1.1B+20% | $1.2B+44% | |
| Interest expense | $66M+5% | $65M+2% | $69M+6% | $77M+10% | $79M+20% | $80M+23% | $82M+19% | $90M+17% | $87M+10% | $90M+13% | $90M+10% | $96M+7% |
| Pre-tax income | $610M+149% | $505M+28% | $608M+37% | $420M−1% | $669M+10% | $585M+16% | $805M+32% | $941M+124% | $939M+40% | $700M+20% | $1.2B+44% | $1.1B+13% |
| $105M+84% | $1M−100% | $115M−12% | $98M−37% | $200M+91% | $23M+2200% | $133M+16% | $146M+49% | $183M−9% | $30M+30% | −$176M | $155M+6% | |
| Net income | $504M+168% | $505M+261% | $494M+57% | $324M+20% | $468M−7% | $566M+12% | $674M+36% | $797M+146% | $755M+61% | $672M+19% | $1.3B+99% | $907M+14% |
| $0.34+183% | $0.34+278% | $0.33+57% | $0.22+22% | $0.32−6% | $0.38+12% | $0.45+36% | $0.53+141% | $0.51+59% | $0.45+18% | $0.90+100% | $0.61+15% | |
| 1.5B+2% | 1.5B+2% | 1.5B+3% | 1.5B+2% | 1.5B+1% | 1.5B+1% | 1.5B+1% | 1.5B+1% | 1.5B+1% | 1.5B+0% | 1.5B+0% | 1.5B−1% |
EPS, diluted: 17 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY08 to Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 13 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $5.1B | $4.8B to $5.3B | $0.73 | $0.66 to $0.78 | 16 |
| Q4 FY26 | $5.4B | $5.2B to $5.7B | $0.83 | $0.82 to $0.85 | 14 |
| Q1 FY27 | $5.4B | $5.2B to $5.6B | $0.80 | $0.76 to $0.86 | 8 |
| Q2 FY27 | $5.6B | $5.4B to $5.9B | $0.85 | $0.81 to $0.91 | 6 |
| Q3 FY27 | $5.5B | $5.3B to $5.8B | $0.83 | $0.79 to $0.89 | 6 |
| Q4 FY27 | $5.7B | $5.5B to $6B | $0.88 | $0.84 to $0.94 | 12 |
| Q1 FY28 | $5.8B | $5.6B to $6.1B | $0.90 | $0.85 to $0.96 | 13 |
| Q2 FY28 | $6.1B | $5.9B to $6.4B | $0.95 | $0.90 to $1.02 | 7 |
Peers
Companies in Medical - Devices nearest Boston Scientific's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BSXBoston Scientific | $66.2B | 18.5× | 67.0× | 14.1× | 3.2× | +14% | 17.5% |
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| ABTAbbott Laboratories | $179.4B | 38.7× | 36.7× | 17.7× | n/m | n/m | n/m |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| Peer median | $51.3B | 30.9× | 36.7× | 18.5× | 3.9× | +9% | 14.2% |
Investors who own it
Investors we follow who held Boston Scientific at the end of Jun 30, 2026, from their 13F filings.
- Lee AinslieMaverick Capital2.3% of portfolioadded
- Polen CapitalPolen Capital0.0% of portfoliotrimmed
More on Boston Scientific
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 17Medical device stocks with the highest profit margins
- #10of 51Healthcare stocks with the lowest forward PE
- #3of 13Medical device stocks with the highest free cash flow yield
- #3of 13Medical device stocks with the lowest EV/EBIT
- #3of 13Medical device stocks with the lowest PE ratio
- #5of 12Medical device stocks with the fastest earnings growth
- #8of 17Medical device stocks with the fastest revenue growth
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .